Related Experiment Video
Updated: Aug 30, 2026

Application of Consistent Massage-Like Perturbations on Mouse Calves and Monitoring the Resulting Intramuscular Pressure Changes
Published on: September 20, 2019
[The treatment of inflammatory muscle diseases]
1Service de médecine interne I, Hôpital Salpétrière, Paris. patrick.cherin@psl.ap-hop-paris.fr
Abstract:
THE TREATMENT OF DM AND PM: Among primary inflammatory muscle diseases, there are three principle subsets depending on immuno-histochemical and clinical aspects: dermatomyositis (DM), polymyositis (PM) and inclusion body myositis (IBM). Despite their physiopathogenic differences, the treatment of PM and DM is very similar. It relies on principally on oral corticosteroid therapy, occasionally initiated via the intravenous route and which is active in 50 to 70% of cases. In patient with primary or secondary resistance, intolerance or dependence regarding corticosteroids, a second treatment line with immunosuppressive agents or intravenous immunoglobulin should be added.
In The Future:
Methrotrexate or azathioprine are still the most commonly used immunosuppressors today. However, the imminent launch of new molecules such as anti-TNF agents and new immunosuppressors suggest that interesting therapeutic alternatives may soon be available. INCONSISTENT EFFICACY IN IBM: However, the treatment of IBM remains controversial. Physiotherapy is crucial. The moderate and inconsistent efficacy with corticosteroids and various immunomodulators suggests a predominately degenerative physiopathogenic mechanism, and/or reflects the far too late onset of treatment at the muscular involvement stage of the disease.
Related Concept Videos
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Skeletal Muscle Relaxants: Therapeutic Uses
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
Classification of Skeletal Muscle Relaxants
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents